Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $15.80.

Several brokerages have issued reports on ZURA. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently made changes to their positions in ZURA. Charles Schwab Investment Management Inc. grew its holdings in shares of Zura Bio by 51.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after purchasing an additional 98,972 shares during the last quarter. Valence8 US LP bought a new stake in shares of Zura Bio in the 3rd quarter worth about $71,000. The Manufacturers Life Insurance Company bought a new stake in shares of Zura Bio in the 3rd quarter worth about $71,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Zura Bio in the 3rd quarter worth about $46,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth about $111,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Down 1.6 %

Shares of ZURA stock opened at $1.26 on Monday. Zura Bio has a 1 year low of $1.10 and a 1 year high of $6.35. The firm’s fifty day simple moving average is $1.73 and its 200 day simple moving average is $2.99.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.